TSGene 2.0: an updated literature-based knowledgebase for tumor suppressor genes
By Min Zhao, P. Kim, R. Mitra, Junfei Zhao, Zhongming Zhao. Nucleic Acids Res., 2015
353 citations recorded by the source corpus.
Tumor suppressor genes (TSGs) are a major type of gatekeeper genes in the cell growth. A knowledgebase with the systematic collection and curation of TSGs in multiple cancer types is critically important for further studying their biological functions as well as for developing therapeutic strategies. Since its development in 2012, the Tumor Suppressor Gene database (TSGene), has become a popular resource in the cancer research community. Here, we reported the TSGene version 2.0, which has substantial updates of contents (e.g. up-to-date literature and pan-cancer genomic data collection and curation), data types (noncoding RNAs and protein-coding genes) and content accessibility. Specifically, the current TSGene 2.0 contains 1217 human TSGs (1018 protein-coding and 199 non-coding genes) curated from over 9000 articles. Additionally, TSGene 2.0 provides thousands of expression and mutation patterns derived from pan-cancer data of The Cancer Genome Atlas. A new web interface is available at http://bioinfo.mc.vanderbilt.edu/TSGene/. Systematic analyses of 199 non-coding TSGs provide numerous cancer-specific non-coding mutational events for further screening and clinical use. Intriguingly, we identified 49 protein-coding TSGs that were consistently down-regulated in 11 cancer types. In summary, TSGene 2.0, which is the only available database for TSGs, provides the most updated TSGs and their features in pan-cancer.
Subfields: Molecular Biology
View Paper: https://www.semanticscholar.org/paper/bc767d2b400b0a9bea3d104dc59d31170535cf39
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Majewski
- T. Hartley
- Toby Dylan Hocking
- K. Kernohan
- N. Alirezaie
Citations in the corpus
- ClinPred: Prediction Tool to Identify Disease-Relevant Nonsynonymous Single-Nucleotide Variants. (2018, methodology): “Gavin applied AFs equal to 0.00346 in ExAC and CADD > 15 as the fixed thresholds for defining variants as pathogenic.”